B. Riley Securities Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $9
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Kalpit Patel initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and a price target of $9.

April 30, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B. Riley Securities has initiated coverage on Ovid Therapeutics with a Buy rating and set a price target of $9.
Analyst ratings, especially with a Buy recommendation, can positively influence investor sentiment and potentially lead to an increase in stock price. The setting of a price target significantly higher than the current trading price can signal expected upside, attracting investor interest.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100